High-density lipoprotein cholesterol and risk of ischemic stroke mortality: A 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study

Stroke

Volumn 28, Issue 1, 1997, Pages 83-87

  Tanne, David ^b   Yaari, Shlomit ^c   Goldbourt, Uri ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c BAR ILAN UNIVERSITY   (Israel)

Author keywords

atherosclerosis; cerebral infarction; Israel; lipoproteins, HDL; mortality; risk factors

Indexed keywords

ADULT; ARTICLE; ATHEROSCLEROSIS; BRAIN INFARCTION; CHOLESTEROL BLOOD LEVEL; HUMAN; ISRAEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STROKE;

EID: 0031028461     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.28.1.83     Document Type: Article

References (35)

1. Gordon DJ, Rifkind BM. High-density lipoprotein: the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
2. Wolf PA, Belanger AJ, D'Agostino RB. Management of risk factors. Neurol Clin. 1992;10:167-191.
3. Gorelick PB. Stroke prevention. Arch Neurol. 1995;52:347-355.
4. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
5. American College of Physicians. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglycerides levels as screening tests for preventing coronary heart disease in adults. Ann Intern Med. 1996;14:515-517.
6. Postiglione A, Napoli C. Hyperlipidemia and atherosclerotic cerebrovascular disease. Curr Opin Lipidol. 1995;6:236-242.
7. Tell GS, Crouse PJR, Furberg CD. Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis: a review. Stroke. 1988;19:423-430.
8. Quizilbash N, Duffy SW, Warlow C, Mann J. Lipids are risk factors for ischemic stroke: overview and review. Cerebrovasc Dis. 1992;2:127-136.
9. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease and death: the Framingham Study. Arch Intern Med. 1981;141:1128-1131.
10. Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ. 1994;309:11-15.
11. Goldbourt U, Yaari S, Medalie JH. Factors predictive of long-term coronary heart disease mortality among 10,059 male Israeli civil servants and municipal employees: a 23-year mortality follow-up in the Israeli Ischemic Heart Disease Study. Cardiology. 1993;82:100-121.
12. Anderson JT, Keys A. Cholesterol in serum lipoprotein fraction. Clin Chem. 1956;21:145-159.
13. Burstein M, Samaille J. Sur une dosage rapid du cholesterol lie aux alpha- et aux beta-lipoprotein du serum. Clin Chim Acta. 1960;5: 609-611.
14. International Classification of Diseases, 9th Revision, Clinical Modification. Ann Arbor, Mich: Edwards Bros; 1981.
15. Yaari S, Goldbourt U. A SAS program for evaluating person years of risk in cohort studies. Comp Biol Med. 1989;19:353-359.
16. Cox DR. Regression models and life-tables. J R Stat Soc (Ser B). 1972;34:187-202.
17. Breslow NE. Analysis of survival data under the proportional hazards model. Int Stat Rev. 1975;43:45-58.
18. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet. 1995;346:1647-1653.
19. Atkins D, Psaty BM, Koepsell TD, Longstreth WT Jr, Larson EB. Cholesterol reduction and the risk of stroke in men: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1993;119:136-145.
20. Herbert PR, Gaziano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med. 1995;155:50-55.
21. Neaton JD, Wentworth DN, Cutler J, Stamler J, Kuller L, for the Multiple Risk Factor Intervention Trial Research Group. Risk factors for death from different types of stroke. Ann Epidemiol. 1993;3: 493-499.
22. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Survival Study Group (4S). Lancet. 1994;344: 1383-1389.
23. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GBJ. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation. 1995;92:2419-2425.
24. Davis CE, Rifkind BM, Brenner H, Gordon DJ. A single cholesterol measurement underestimates the risk of coronary heart disease: an empirical example from the Lipid Research Clinics mortality follow-up study. JAMA. 1991;264:3044-3046.
25. Iso H, Jacobs DR, Goldman L. Accuracy of death certificate diagnosis of intracranial hemorrhage and ischemic stroke. Am J Epidemiol. 1990;132:993-998.
26. Adams RJ, Caroll RM Nichols FT, McNair N, Feldman DS, Feldman EB, Thompson WO. Plasma lipoproteins in cortical versus lacunar infarction. Stroke. 1989;20:346-354.
27. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521-1526.
28. Rader DJ, Brewer HB Jr. Lipids, apolipoproteins and lipoproteins. In: Goldbourt U, de Faire U, Berg K, eds. Genetic Factors in Coronary Heart Disease. Norwell, Mass: Kluwer Academic Publishers; 1994:83-103.
29. Schmitz G, Lackner KJ. High density lipoproteins and atherosclerosis. Curr Opin Lipidol. 1993;4:392-401.
30. Sagiv M, Goldbourt U. The influence of physical exercise on blood levels of HDL-cholesterol: implications for the risk of coronary heart disease. Int J Sports Med. 1994;15:261-266.
31. Taskinen MR, Nikkila EA, Valimaki M, Sane T, Kuusi T, Kesaniemi A, Ylikahri R: Alcohol-induced changes in serum lipoproteins and in their metabolism. Am Heart J. 1987;113:458-464.
32. Goldbourt U, Medalie JH. Characteristics of smokers, non-smokers and ex-smokers among 10,000 adult males in Israel, II: physiological, biochemical and genetic characteristics. Am J Epidemiol 1977; 105:75-86.
33. Wood PD, Stefanick MI, Dreon DM, Frey-Hewitt B, Garay SC, Williams PT, Superko HR, Fortmann SP, Albers JJ, Vranizan KM, Elsworth NM, Terry RB, Haskell WL. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N Engl J Med. 1988;319:1173-1179.
34. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E, Kishon Y, Caspi A, Weisbort J, Mandelzweig L, Abinader E, Aharon L, Braun S, David D, Flich M, Friedman Y, Kristal N, Leil N, Markiewicz W, Marmor A, Palant A, Pelled B, Rabinowitz B, Reisin L, Roguin N, Rosenfeld T, Schlesinger Z, Sclarovsky S, Sherf L, Tzivoni D, Zahavi I, Zion M, Brunner D, for the Bezafibrate Infarction Prevention Study Group. Rationale and design of a secondary prevention trial of elevating serum high density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease: the Bezafibrate Infarction Prevention Trial. Am J Cardiol. 1993;71:909-915.
35. Rubins HB, Robins SJ, Iwane WK, Boden WE, Elam MB, Fye CL, Gordon DJ, Sachaefer EJ, Schectman G, Wittes JT. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for the secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol. 1993;71:45-52.